Paper24978464
Targeted radiotherapy with gold nanoparticles: current status and future perspectives.
Ngwa W and 7 others. Nanomedicine (Lond), 2014. Cited by 126 papers, by iCite.
Cite this record
ConductScience Library. Targeted radiotherapy with gold nanoparticles: current status and future perspectives. Papers, record 24978464. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/24978464
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S., Review
- PubMed
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Gold | Major topic |
| Metal Nanoparticles | Major topic |
| Neoplasms | Major topic |
| Humans | |
| Nanomedicine | |
| Nanotechnology |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| K01 CA172478 | NCI NIH HHS | United States | K01CA172478 | PubMed and NIH | NIH RePORTER |
| R03 CA164645 | NCI NIH HHS | United States | R03CA164645 | PubMed and NIH | NIH RePORTER |
| R41 EY024197 | NEI NIH HHS | United States | R41EY024197 | PubMed and NIH | NIH RePORTER |
References169
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 17021318 | Ranibizumab for neovascular age-related macular degeneration. | N Engl J Med | 2006 | https://conductscience.org/library/papers/17021318 | PubMed |
| 2 | 19879699 | Biological in situ dose painting for image-guided radiation therapy using drug-loaded implantable devices. | Int J Radiat Oncol Biol Phys | 2010 | https://conductscience.org/library/papers/19879699 | PubMed |
| 3 | 19700816 | Contrast-enhanced radiotherapy: feasibility and characteristics of the physical absorbed dose distribution for deep-seated tumors. | Phys Med Biol | 2009 | https://conductscience.org/library/papers/19700816 | PubMed |
| 4 | 18712584 | Intravascular delivery of particulate systems: does geometry really matter? | Pharm Res | 2009 | https://conductscience.org/library/papers/18712584 | PubMed |
| 5 | 23201628 | Enhanced proton treatment in mouse tumors through proton irradiated nanoradiator effects on metallic nanoparticles. | Phys Med Biol | 2012 | https://conductscience.org/library/papers/23201628 | PubMed |
| 6 | 11893639 | Potential improvements in the therapeutic ratio of prostate cancer irradiation: dose escalation of pathologically identified tumour nodules using intensity modulated radiotherapy. | Br J Radiol | 2002 | https://conductscience.org/library/papers/11893639 | PubMed |
| 7 | 23302438 | Impact of beam quality on megavoltage radiotherapy treatment techniques utilizing gold nanoparticles for dose enhancement. | Phys Med Biol | 2013 | https://conductscience.org/library/papers/23302438 | PubMed |
| 8 | 17308123 | Sphingosine-1-phosphate protects proliferating endothelial cells from ceramide-induced apoptosis but not from DNA damage-induced mitotic death. | Cancer Res | 2007 | https://conductscience.org/library/papers/17308123 | PubMed |
| 9 | 21858925 | Nanoscience and nanotechnology: evolving definitions and growing footprint on the scientific landscape. | Small | 2011 | https://conductscience.org/library/papers/21858925 | PubMed |
| 10 | 21915155 | Enhanced relative biological effectiveness of proton radiotherapy in tumor cells with internalized gold nanoparticles. | Appl Phys Lett | 2011 | https://conductscience.org/library/papers/21915155 | PubMed |
| 11 | 24588231 | Biogenic gold nanoparticles: As a potential candidate for brain tumor directed drug delivery. | Artif Cells Nanomed Biotechnol | 2015 | https://conductscience.org/library/papers/24588231 | PubMed |
| 12 | 19118040 | Intratumoral delivery of beta-lapachone via polymer implants for prostate cancer therapy. | Clin Cancer Res | 2009 | https://conductscience.org/library/papers/19118040 | PubMed |
| 13 | 11234875 | Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. | Clin Cancer Res | 2001 | https://conductscience.org/library/papers/11234875 | PubMed |
| 14 | 2384804 | Inhomogeneous deposition of radiopharmaceuticals at the cellular level: experimental evidence and dosimetric implications. | J Nucl Med | 1990 | https://conductscience.org/library/papers/2384804 | PubMed |
| 15 | 21830745 | 16-Gy low-voltage x-ray irradiation followed by as-needed ranibizumab therapy for AMD: 6-month outcomes of a "radiation-first" strategy. | Ophthalmic Surg Lasers Imaging | 2011 | https://conductscience.org/library/papers/21830745 | PubMed |
| 16 | 20080552 | Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles. | Proc Natl Acad Sci U S A | 2010 | https://conductscience.org/library/papers/20080552 | PubMed |
| 17 | 20225865 | Gold nanoparticles for the improved anticancer drug delivery of the active component of oxaliplatin. | J Am Chem Soc | 2010 | https://conductscience.org/library/papers/20225865 | PubMed |
| 18 | 23423979 | Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. | Cancer Res | 2013 | https://conductscience.org/library/papers/23423979 | PubMed |
| 19 | 20153731 | Bioaccumulation and toxicity of gold nanoparticles after repeated administration in mice. | Biochem Biophys Res Commun | 2010 | https://conductscience.org/library/papers/20153731 | PubMed |
| 20 | 23638079 | Selective targeting of brain tumors with gold nanoparticle-induced radiosensitization. | PLoS One | 2013 | https://conductscience.org/library/papers/23638079 | PubMed |
Cited by66
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 126 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42570096 | Range of dose enhancement factor for gold nanoparticles in radiotherapy using Monte Carlo simulations. | Radiat Environ Biophys | 2026 | https://conductscience.org/library/papers/42570096 | PubMed |
| 41743230 | Tumor radiosensitization with gold nanoparticles: evolving strategies to improve tumoral gold uptake and catalyze future clinical translation. | ACS Nano Med | 2026 | https://conductscience.org/library/papers/41743230 | PubMed |
| 41189671 | Advancing cancer radiotherapy: Harnessing radiosensitizers and nanotechnology for enhanced tumor control. | Int J Pharm X | 2025 | https://conductscience.org/library/papers/41189671 | PubMed |
| 40050802 | Engineered multifunctional nanoparticles for enhanced radiation therapy: three-in-one approach for cancer treatment. | Mol Cancer | 2025 | https://conductscience.org/library/papers/40050802 | PubMed |
| 40006543 | Exploring the Potential of Gold Nanoparticles in Proton Therapy: Mechanisms, Advances, and Clinical Horizons. | Pharmaceutics | 2025 | https://conductscience.org/library/papers/40006543 | PubMed |
| 39590321 | Preliminary Study on Lutetium-177 and Gold Nanoparticles: Apoptosis and Radiation Enhancement in Hepatic Cancer Cell Line. | Curr Issues Mol Biol | 2024 | https://conductscience.org/library/papers/39590321 | PubMed |
| 38470761 | An Optimized Method for Evaluating the Potential Gd-Nanoparticle Dose Enhancement Produced by Electronic Brachytherapy. | Nanomaterials (Basel) | 2024 | https://conductscience.org/library/papers/38470761 | PubMed |
| 37555189 | Emulsion Technology in Nuclear Medicine: Targeted Radionuclide Therapies, Radiosensitizers, and Imaging Agents. | Int J Nanomedicine | 2023 | https://conductscience.org/library/papers/37555189 | PubMed |
| 36980778 | The Promise of Nanoparticles-Based Radiotherapy in Cancer Treatment. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/36980778 | PubMed |
| 36979684 | The Usefulness of Nanotechnology in Improving the Prognosis of Lung Cancer. | Biomedicines | 2023 | https://conductscience.org/library/papers/36979684 | PubMed |
| 36743265 | Gold nanoparticles capped with L-glycine, L-cystine, and L-tyrosine: toxicity profiling and antioxidant potential. | J Mater Sci | 2023 | https://conductscience.org/library/papers/36743265 | PubMed |
| 35931743 | Enhancing nanoparticle accumulation in two dimensional, three dimensional, and xenograft mouse cancer cell models in the presence of docetaxel. | Sci Rep | 2022 | https://conductscience.org/library/papers/35931743 | PubMed |
| 35478920 | A model of modified meta-iodobenzylguanidine conjugated gold nanoparticles for neuroblastoma treatment. | RSC Adv | 2021 | https://conductscience.org/library/papers/35478920 | PubMed |
| 35336040 | Image-Based Quantification of Gold Nanoparticle Uptake and Localization in 3D Tumor Models to Inform Radiosensitization Schedule. | Pharmaceutics | 2022 | https://conductscience.org/library/papers/35336040 | PubMed |
| 35057061 | Incorporation of Low Concentrations of Gold Nanoparticles: Complex Effects on Radiation Response and Fate of Cancer Cells. | Pharmaceutics | 2022 | https://conductscience.org/library/papers/35057061 | PubMed |
| 34860272 | Gold-nanoparticle-enriched breast tissue in breast cancer treatment using the INTRABEAM® system: a Monte Carlo study. | Radiat Environ Biophys | 2022 | https://conductscience.org/library/papers/34860272 | PubMed |
| 34771534 | Application of High-Z Gold Nanoparticles in Targeted Cancer Radiotherapy-Pharmacokinetic Modeling, Monte Carlo Simulation and Radiobiological Effect Modeling. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/34771534 | PubMed |
| 34753117 | Improving dose calculation accuracy in preclinical radiation experiments using multi-energy element resolved cone-beam CT. | Phys Med Biol | 2021 | https://conductscience.org/library/papers/34753117 | PubMed |
| 34104817 | Current role of nanoparticles in the treatment of lung cancer. | J Clin Transl Res | 2021 | https://conductscience.org/library/papers/34104817 | PubMed |
| 33989429 | EURADOS STRATEGIC RESEARCH AGENDA 2020: VISION FOR THE DOSIMETRY OF IONISING RADIATION. | Radiat Prot Dosimetry | 2021 | https://conductscience.org/library/papers/33989429 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| KLK3 | 354 | PubTator's text mining | https://conductscience.org/library/genes/354 | NCBI Gene |
| TF | 7018 | PubTator's text mining | https://conductscience.org/library/genes/7018 | NCBI Gene |
| VEGFA | 7422 | PubTator's text mining | https://conductscience.org/library/genes/7422 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/24978464
GET https://conductscience.org/api/papers/v1/24978464/references?page=2